Datapoint: Lilly Pulls Olumiant in Lupus

Eli Lilly and Incyte on Jan. 28 said they have ended Olumiant’s Phase 3 trial for lupus, citing mixed results. The companies also gave an update on the JAK inhibitor’s status in atopic dermatitis, warning that the agency may issue a Complete Response Letter. For the treatment of rheumatoid arthritis, Olumiant currently holds covered or better status for 67% of all insured lives under the pharmacy benefit. About 11% of all covered lives have preferred access to Olumiant, with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 1/31/22

0

0

0 Comments

0

0

• Datapoint